Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,824.00
Bid: 1,816.00
Ask: 1,826.00
Change: -16.00 (-0.87%)
Spread: 10.00 (0.551%)
Open: 1,870.00
High: 1,870.00
Low: 1,814.00
Prev. Close: 1,840.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

15 Nov 2007 07:01

Genus PLC15 November 2007 For Immediate Release 15 November 2007 Genus plc Annual General Meeting At the Annual General Meeting of Genus plc ("Genus") to be held today at 2.30pm,the Chairman, John Hawkins, will make the following statement: "During the financial year to 30 June 2007, the first full year since wecompleted the Sygen acquisition that so dramatically changed the potential ofthe Company, we have achieved strong business growth and increased cost productivity by successfully integrating the acquired business. In the years tocome, Genus' progress will continue to benefit from the increased opportunitiesarising from that acquisition. In the Annual Report and Financial Statements for last year's trading, weconfirmed the Board's intention to divest the remaining non-core businesses todrive down debt, while ensuring that such divestments would realise goodshareholder value. We also stated that we would continue to seek to increaseliquidity in Genus shares. In these pursuits, in October, we completed the sale of the only remainingshrimp business, SyAqua Mexico and last week, we announced the disposal ofHTSPE, the Development Consulting business. To increase liquidity in Genus shares and to reduce debt, on 6 November, weannounced that we had raised £19.4m from placing 2.7 million shares withinstitutions at £7.20 per share. This placing is expected to be earningsenhancing as it reduces group debt to below £100m, thereby reducing the Group'saverage interest costs by 25 basis points. Also to improve liquidity, in parallel, we concluded a small shareholder buy-back and placing with institutional shareholders, for a total of 1.15 millionshares at a price of up to £7.30 per share. 1,692 small shareholders in Genustook advantage of this low cost dealing mechanism. Trading for the new financial year has started well in the anticipated improvingagricultural climate. For the first quarter, trading has been on plan, despitethe weakening dollar. While we expect some uncertainty to continue in Europe,as the industry adjusts to the challenges of a changing environment, buoyancy inother markets should more than compensate for this. The Board was delighted to announce, on 12 November, the admission of trading inGenus' shares to the Official List of the London Stock Exchange. Genus wasoriginally formed when the Milk Marketing Board was privatised in 1994 and firsttraded as a Public Company on OFEX in 1997, progressing to AIM in 2000. Nowwith a Market Capitalisation of around £420m, Genus is ranked at about 350 ofthe leading FTSE companies. In closing my review, I would like to offer my thanks to my colleagues on theBoard for their support in our achievements, over the last 10 years, butparticularly for this year. With the Company's move to the Official List, Edwin White, the Company's senior non-executive director, has indicated hisintention to leave the Board during the current financial year and the Companyis in the process of recruiting Mr White's successor. I would also like to compliment the management team and the staff at Genus fortheir achievements over this ten year period of considerable change anddevelopment of the company. The Board believes we have created a company with considerable market strength,good R&D, proven skills in managing both organic and acquisition growth andoperating cost advantages from integrating the recent acquisition. This bodes well for the future of Genus in improving market conditions. To conclude, I would like to offer the Board's commitment to Genus' shareholdersthat, as we begin a new chapter in the development of Genus as a ListedCompany, we will continue to build on the success that we have so far achieved." For further information please contact: Genus plc Tel: 01256 347 100Richard Wood, Chief ExecutiveMartin Boden, Finance Director Landsbanki Securities (UK) Limited Tel: 020 7426 9000Financial Advisor & Joint BrokerShaun Dobson Panmure Gordon (UK) Limited Tel: 020 7459 3600Joint BrokerMark Lander Buchanan Communications Tel: 020 7466 5000Charles RylandSuzanne BrocksChristian Goodbody This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Feb 20167:00 amRNSINTERIM RESULTS
1st Feb 20161:22 pmRNSBlocklisting Interim Review
4th Jan 20165:40 pmRNSTotal Voting Rights
11th Dec 20153:14 pmRNSDirector/PDMR Shareholding
9th Dec 20154:30 pmRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSTackles major pig disease with breakthrough tech
1st Dec 20154:54 pmRNSHolding(s) in Company
1st Dec 20154:46 pmRNSTotal Voting Rights
19th Nov 20152:52 pmRNSResult of AGM
19th Nov 20157:00 amRNSAGM - TRADING UPDATE
2nd Nov 20153:04 pmRNSTotal Voting Rights
22nd Oct 20155:48 pmRNSHolding(s) in Company
21st Oct 20156:10 pmRNSDirector/PDMR Shareholding
15th Oct 201512:46 pmRNSAnnual Report and Notice of AGM
1st Oct 20153:00 pmRNSTotal Voting Rights
15th Sep 201511:00 amRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSPreliminary Results
3rd Aug 20152:00 pmRNSBlocklisting Interim Review
30th Jun 20152:00 pmRNSTotal Voting Rights
29th Jun 20152:00 pmRNSChange of Registered Office
29th May 20152:00 pmRNSTotal Voting Rights
12th May 20157:00 amRNSCapital Markets Event and Trading Update
11th May 20152:00 pmRNSHolding(s) in Company
7th May 20152:21 pmRNSHolding(s) in Company
30th Apr 20152:00 pmRNSTotal Voting Rights
14th Apr 20152:00 pmRNSDirector/PDMR Shareholding
13th Apr 20155:06 pmRNSHolding(s) in Company
1st Apr 20157:00 amRNSCompletion of acquisition
31st Mar 20154:04 pmRNSTotal Voting Rights
19th Mar 20155:46 pmRNSDirector/PDMR Shareholding
12th Mar 20152:09 pmRNSDirector/PDMR Shareholding
9th Mar 20151:24 pmRNSDirector Declaration
27th Feb 20152:00 pmRNSTotal Voting Rights
24th Feb 201511:00 amRNSHolding(s) in Company
24th Feb 20157:00 amRNSInterim Results
16th Feb 20157:00 amRNSAcquisition of 51% of In Vitro Brasil
2nd Feb 20151:22 pmRNSBlock Listing Six Monthly Return
31st Dec 201412:01 pmRNSTotal Voting Rights
12th Dec 201410:44 amRNSDirector/PDMR Shareholding
1st Dec 20144:36 pmRNSTotal Voting Rights
21st Nov 20144:03 pmRNSDirector/PDMR Shareholding
14th Nov 20143:42 pmRNSResult of AGM
14th Nov 20147:00 amRNSTrading Update
31st Oct 201412:20 pmRNSTotal Voting Rights
22nd Oct 20149:29 amRNSDirector/PDMR Shareholding
10th Oct 20145:58 pmRNSHolding(s) in Company
8th Oct 20143:47 pmRNSAnnual Report and Annual General Meeting
3rd Sep 20147:00 amRNSPreliminary Results
3rd Sep 20147:00 amRNSPorcine Multiplication Agreement in China
29th Aug 20143:08 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.